Skip to main content

This job has expired

You will need to login before you can apply for a job.

Scientist II/Senior Scientist, In Vivo Immunology

Employer
Nurix Therapeutics
Location
San Francisco, CA, United States
Start date
Jun 1, 2021

View more

Discipline
Science/R&D, Biotechnology, Pharmacology
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Biotech Bay

Job Details

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix's extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix's drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix's wholly owned pipeline comprises targeted protein degraders of Bruton's tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Job Summary:

We are seeking a highly skilled and motivated in vivo pharmacologist to lead efforts in oncology, immuno-oncology, and inflammation. The ideal candidate will have expertise in small molecule PK/PD studies, xenograft and syngeneic tumor models, inflammatory disease models, and immune cell profiling by flow cytometry. This role will support novel drug development projects from early lead optimization through clinical candidate selection. Duties include planning, execution and analysis of in vivo experiments, management of work within the preclinical pharmacology team, and management of projects at CROs. This individual will work closely with scientists from cross-functional disciplines and present findings to project teams. The candidate must be self-driven, highly organized, and enjoy working in a creative and dynamic team environment.

If you are intrigued by the opportunity to work with a passionate team of scientists focused on improving patient's lives with first-in-class therapies, please consider applying.

Qualifications:
  • Ph.D. in pharmacology, immunology, cancer biology or a related field. Scientist II requires 3+ years of industry experience; Senior Scientist requires 6+ years
  • Expertise in oncology, immuno-oncology, inflammation and in vivo models of disease
  • Proven ability to identify and develop disease models for preclinical drug development
  • Management experience of direct reports required
  • Experience as lead pharmacology representative on project teams required
  • Expertise with flow cytometer-based profiling of immune cells required
  • Expertise in small molecule drug development and PK/PD assay technologies
  • Expertise with hit-to-lead optimization and establishment of PK/PD relationships
  • Knowledge of transgenic model generation and phenotypic characterization desired
  • Experience writing preclinical reports for IND filings desired
  • Requires excellent communication and presentation skills

To apply, submit your resume to: https://www.nurixtx.com/culture-careers/job-openings/

Company

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.

Company info
Website
Phone
415-660-5320
Location
1700 Owens Street
Suite 205
San Francisco
California
94158
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert